Menlo Therapeutics Inc., a clinical stage pharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant, VPD-737) for the treatment of pruritus (itch). ¬†Over the past 16 months, Menlo Therapeutics established direct operations to advance serlopitant and recruited an experienced drug development management team including: Steven Basta, CEO. Mr. … Read More